Date: Tuesday January 24, 2023

Time: 7:30 PM – 8:30 PM

Topic: Retina cases that shock and awe

Speakers: Dr. Jose Pulido

Zoom Link – Register in advance for this webinar:

After registering, you will receive a confirmation email containing information about joining the webinar.

Date: Monday December 12, 2022

Time: 5:30 PM – 6:30 PM

Topic: Primary angle closure glaucoma in the 21st century

Speakers: Dr. Vital P. Costa

Location – Toronto Western Hospital, Fell Pavilion, 6th Floor, Room FP 6-103,

399 Bathurst Street, Toronto, ON M5T 2S8

OR:

Zoom Link – Register in advance for this webinar:

After registering, you will receive a confirmation email containing information about joining the webinar.

​OBJECTIVES:

1. To present a classification for angle closure glaucoma to enable effective therapy.
2. To review the evidence for the treatment of primary angle closure.
3. To discuss surgical challenges and approaches in primary angle closure eyes.

Date: Thursday December 1, 2022

Time: 5:00 PM – 6:00 PM

Topic: Corneal complications of intraocular surgery

Speakers: Dr. Mariana C. Collazos

Zoom Link – Register in advance for this webinar:

After registering, you will receive a confirmation email containing information about joining the webinar.

OBJECTIVES:

1. Define the different types of corneal complications after intraocular surgery
2. Identify risk factor for developing corneal complications after intraocular surgery
3. Discuss the appropriate treatment in every scenario

September 2018

Context: There is a growing trend among body modification enthusiasts to tattoo their eyeballs (specifically the sclera of the eye) and also implant jewellery under the surface layer (conjunctiva) of the eyeball. This is being done unsafely by untrained artists under questionable conditions and leading to a
variety of unfortunate complications, including loss of vision and loss of the eye in some cases. As eye health care professionals, the Manitoba Association of Optometrists (MAO) and the Eye Physicians and Surgeons of Manitoba (EPSOM) are submitting this joint statement calling for a ban of these dangerous practices leading to unnecessary morbidity and loss of vision in members of the unsuspecting public.

Read the Full Position Statement Here

December 2019

Evidence-based clinical practice guidelines for the periodic eye examination in children aged 0-5 years in Canada

The Position Stated is based on current evidence and expert medical opinion available at the
time and was endorsed by the COS in November 2019.

Background: As eye disease before age 5 years is common, some form of vision screening should be performed on children before attending primary school. However, the lack of consistent national recommendations creates confusion for patients, eye care professionals, and governments alike.

Download the full guidelines here

November 2019

Evidence-Based Recommendations for the Risk of Acute Angle Closure Glaucoma with Routine Use of Hyoscine-n-Butylbromide (Buscopan) for Gastroenterological Procedures.

The Position Stated is based on current evidence and expert medical opinion available at the time and was endorsed by the COS in November 2019.

Background: Hyoscine-n-butylbromide (Buscopan) is a commonly used anticholinergic medication for
gastroenterological endoscopic procedures because of its ability to induce smooth muscle relaxation and decrease spasm. It can also be used for radiologic procedures of the gastrointestinal tract. Buscopan may increase detection of colorectal adenoma by up to 30%, thus this medication should not be withheld needlessly.

Read the full position statement here.

July 21, 2022

Advisory Statement: Regarding Light Therapy (Photobiomodulation) for Macular Degeneration

Discussion: Patients with early dry macular degeneration often have relatively normal vision. As the disease progresses to advanced stages, patients can have both a gradual and/or sudden loss of central vision. There are no proven pharmacologic treatments for dry ARMD, however age-related eye disease study (AREDS) vitamin supplementation has been shown in large, randomized trials to decrease the risk of progressing to advanced macular degeneration. Canadian patients have coverage and access to effective, large randomized clinical trial-proven pharmacologic treatments for wet macular degeneration.

Read the full advisory statement here

April 2, 2019

Position Statement by the Canadian Ophthalmological Society (COS) Regarding Diversity and Inclusion

The Canadian Ophthalmological Society (COS) encourages inclusivity and opposes discrimination based on (but not limited to) religion, race, citizenship, country or ethnic origin, language, age, political affiliation or opinion, sex, sexual orientation, gender identity and expression, cognitive or physical ability, and economic status. As the recognized unified voice for ophthalmology in Canada, COS is strengthened by its diversity. COS members come from broad and diverse backgrounds, and this variety of experiences, training, and personal qualities is fundamental to ophthalmologists’ ability to provide the highest quality and culturally competent care for all patients.

Open source ophthalmology education for students, residents, fellows, healthcare workers, and clinicians. Produced by the Moran Eye Center in partnership with the Eccles Library